These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 12393688

  • 1. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW.
    Blood; 2003 Feb 15; 101(4):1422-9. PubMed ID: 12393688
    [Abstract] [Full Text] [Related]

  • 2. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
    Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH.
    Blood; 2002 Apr 01; 99(7):2586-91. PubMed ID: 11895797
    [Abstract] [Full Text] [Related]

  • 3. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.
    Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S.
    Blood; 2002 Sep 01; 100(5):1715-20. PubMed ID: 12176892
    [Abstract] [Full Text] [Related]

  • 4. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia.
    Auffermann-Gretzinger S, Eger L, Schetelig J, Bornhäuser M, Heidenreich F, Ehninger G.
    Transplantation; 2007 May 15; 83(9):1268-72. PubMed ID: 17496545
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alemtuzumab for the prevention and treatment of graft-versus-host disease.
    Kanda J, Lopez RD, Rizzieri DA.
    Int J Hematol; 2011 May 15; 93(5):586-593. PubMed ID: 21369856
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
    Brett SJ, Baxter G, Cooper H, Rowan W, Regan T, Tite J, Rapson N.
    Int Immunol; 1996 Mar 15; 8(3):325-34. PubMed ID: 8671618
    [Abstract] [Full Text] [Related]

  • 9. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells.
    Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, Reagan JL, Münz C, Heller G, Young JW.
    J Immunol; 2004 Aug 15; 173(4):2780-91. PubMed ID: 15294997
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
    Lee F, Luevano M, Veys P, Yong K, Madrigal A, Shaw BE, Saudemont A.
    PLoS One; 2014 Aug 15; 9(7):e103254. PubMed ID: 25050704
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Alemtuzumab in stem cell transplantation.
    Hale G.
    Med Oncol; 2002 Aug 15; 19 Suppl():S33-47. PubMed ID: 12180491
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ, Clarke E, Blair A, Evely R, Hale G, Waldmann H, Brookes S, Pamphilon DH.
    Cytotherapy; 2000 Aug 15; 2(1):5-14. PubMed ID: 12042050
    [Abstract] [Full Text] [Related]

  • 16. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R.
    Pediatr Blood Cancer; 2005 Mar 15; 44(3):251-4. PubMed ID: 15390358
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
    Chakrabarti S, Hale G, Waldmann H.
    Transplant Proc; 2004 Jun 15; 36(5):1225-7. PubMed ID: 15251298
    [Abstract] [Full Text] [Related]

  • 20. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
    Giralt S.
    Semin Oncol; 2006 Apr 15; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.